NewAmsterdam Pharma Company N.V.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | — | $22.5M | $45.6M | $14.1M | $102.7M | — |
| Cost of Revenue | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — |
| Operating Expenses | ||||||
| Research & Development | — | $141.8M | $151.4M | $159.4M | $86.7M | $29.0M |
| SG&A Expense | — | $106.4M | $70.4M | $37.6M | $19.5M | $6.0M |
| Operating Income | — | $-225.7M | $-176.3M | $-183.0M | $-3.6M | $-35.0M |
| Operating Margin | — | -1,002.9% | -386.9% | -1,298.6% | -3.5% | — |
| Interest Expense | — | — | — | — | $287.0K | $411.0K |
| Pretax Income | — | $-203.8M | $-241.6M | $-176.9M | $-22.6M | $-41.8M |
| Income Tax Expense | — | — | $-1.0K | $27.0K | — | — |
| Net Income | — | $-203.8M | $-241.6M | $-176.9M | $-22.6M | $-41.8M |
| Net Margin | — | -905.7% | -530.3% | -1,255.8% | -22.0% | — |
| EPS (Basic) | — | $-1.72 | $-2.56 | $-2.15 | $-0.30 | $-0.95 |
| EPS (Diluted) | — | $-1.72 | $-2.56 | $-2.15 | $-0.30 | $-0.95 |
| Shares Outstanding (Basic) | 115.0M | 118.4M | 94.4M | 82.2M | 75.9M | 43.9M |
| Shares Outstanding (Diluted) | 115.0M | 118.4M | 94.4M | 82.2M | 75.9M | 43.9M |
| Dividends Per Share | — | — | — | — | — | — |